Healthcare Industry News: endoscopy
News Release - July 7, 2008
Brian Tinkham Appointed Vice President of Marketing At Cellvizio Inc.PHILADELPHIA, July 7, 2008 (Healthcare Sales & Marketing Network) -- Cellvizio Inc., a leader in in vivo cellular imaging, announced today the appointment of Brian P. Tinkham as vice president of marketing for the company. Cellvizio Inc. is the U.S. subsidiary of Paris-based Mauna Kea Technologies and develops and markets Cellvizio(r), a fundamentally new endoscopic imaging approach which improves patient care by eliminating the need for unnecessary biopsies and enhances the diagnosis of a broad range of diseases via in vivo cellular imaging.
Brian joins Cellvizio from Boston Scientific's endoscopy Division where he held increasing levels of managerial responsibilities in the global marketing, product marketing and sales division groups.
``Brian brings with him a considerable wealth of clinical knowledge in this area and is highly regarded as a key influencer in the gastroenterological physician community,'' said Chris Tihansky, president of Cellvizio Inc. ``He will be a valuable asset to our team as we continue to expand adoption of Cellvizio in the U.S.''
Tinkham has a Bachelor of Arts and Science degree in Marketing from the University of Massachusetts and is currently completing an MBA at Northeastern University in Boston.
Cellvizio is the first and only confocal microscopy system that is compatible with most endoscopes and allows physicians to view live tissue inside the body at the cellular level in dynamic, real-time images at 12 frames per second. Over 1,000 Cellvizio procedures have been completed to date. It has 510(k) clearance from the Food & Drug Administration and the European CE-Mark for use in the gastrointestinal and pulmonary tracts.
Cellvizio Inc. leads the growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques. The Cellvizio(r) system provides microscopic visualization of mucosal tissue and improves clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. Cellvizio Inc. is currently focused on the gastroenterology and pulmonology markets. The company plans to expand into other markets and diseases indications in the future and also has a distribution agreement with Leica Microsystems to sell products for the Small Animal Imaging market in Europe, the U.S. and Japan. For more information about Cellvizio, go to: http://www.cellvizio.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.